EU Authorizes Perioperative Pembrolizumab Plus Enfortumab Vedotin

Company Merck; Pfizer; Astellas Event Type Regulatory (European Commission Authorization) Modality Anti-PD-1 antibody plus Nectin-4 antibody-drug conjugate Asset Pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) Target PD-1; Nectin-4 Disease Area Resectable muscle-invasive bladder cancer (perioperative, cisplatin-eligible) Summary The European Commission authorized pembrolizumab plus enfortumab vedotin before…